Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | HER2-E pCR with anti-HER2-based neoadjuvant therapies

Aleix Prat • 18 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Lapatinib Trastuzumab
PAMELA

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses a meta-analysis that validated the association of the HER2-E subtype with pathological complete response (pCR) following anti-HER2-based neoadjuvant treatments with or without chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Aleix Prat

3:18
Molecular heterogeneity in HER2+ breast cancer and predicting outcomes
Aleix Prat • 7 Dec 2021
6:15
Beyond HER2: dissecting tumor heterogeneity
Aleix Prat • 14 May 2020
3:09
CORALLEEN: kicking chemo?
Aleix Prat • 14 May 2020
3:22
HER2 blockade in HER2-E induces low-proliferative luminal A phenotype
Aleix Prat • 14 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals